Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
Bohl, C.E., Gao, W., Miller, D.D., Bell, C.E., Dalton, J.T.(2005) Proc Natl Acad Sci U S A 102: 6201-6206
- PubMed: 15833816 
- DOI: 10.1073/pnas.0500381102
- Primary Citation of Related Structures:  
1Z95 - PubMed Abstract: 
Carcinoma of the prostate is the most commonly diagnosed cancer in men. The current pharmacological treatment of choice for progressive androgen-dependent prostate cancer is the nonsteroidal antiandrogen, bicalutamide, either as monotherapy or with adjuvant castration or luteinizing hormone-releasing hormone superagonists to block the synthesis of endogenous testosterone ...